A study published in Frontiers in Oncology suggests that salvage chemotherapy administered after immune checkpoint inhibitor (ICI) treatment may improve survival rates for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Immune checkpoint inhibitors have become part of the standard treatment approach for SCCHN, but the survival benefits observed have been limited. Researchers investigated whether adding chemotherapy after ICI therapy – a strategy termed salvage chemotherapy after ICI (SCAI) – could yield improved outcomes.
The findings indicate that SCAI may offer a survival advantage for these patients. Even as the initial use of ICIs has shown promise, the modest gains in survival have prompted exploration of combination strategies. The study focused on patients whose cancer had returned or spread after initial treatment, a particularly challenging clinical scenario.
Current approaches to treating locoregionally recurrent head and neck squamous cell carcinoma (HNSCC) are evolving, with increasing attention being paid to the role of immunotherapy. Salvage surgery remains an important therapeutic option, offering the potential for improved locoregional control, and survival. Though, determining the optimal indications for salvage surgery remains a challenge, with reported five-year survival rates varying widely, from 10% to 61%.
Integrating immunotherapy into surgical protocols, both in primary and salvage settings, is an area of active investigation. Early trials suggest that combining immunotherapy with salvage surgery may enhance survival, reduce recurrence rates, and improve overall outcomes for patients with recurrent or persistent HNSCC. A review assessing current evidence highlights the need for enhanced patient selection and optimized surgical outcomes in the context of immunotherapy.
Further research, including clinical trials incorporating immunotherapy, is underway to refine treatment strategies for HNSCC. A phase II trial evaluating the efficacy and toxicity of Nivolumab after salvage surgery in HNSCC is currently being conducted (ADJORL1).
